“Atossa announced that the preliminary results (PK, tolerability, safety) reported in 3Q18 in the P1 study of topical Endoxifen in male healthy subjects are now final. The company is awaiting the completion of an ongoing P2 study in women with mammographic breast density (MBD, expected 2Q19) to determine the next steps clinically for developing topical Endoxifen in men with breast health issues, including gynecomastia.”,” Maxim Group’s analyst wrote.
ATOS stock traded down $0.07 during midday trading on Wednesday, reaching $1.36. 311,577 shares of the company’s stock traded hands, compared to its average volume of 2,580,248. Atossa Genetics has a 52-week low of $0.80 and a 52-week high of $10.68.
Atossa Genetics Company Profile
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Further Reading: What is the yield curve?
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.